AI Designing Drugs: Navigating the Hype
Insight by Yaron Werber and Steven Mah
Yaron Werber, Biotechnology Analyst and Steven Mah, Life Science and Diagnostic Tools Analyst interview biotherapeutic executives on how artificial intelligence is revolutionizing drug discovery for autoimmune disorders and oncology.
They discuss using machine learning and AI to expedite drug discovery and development, how they aid in designing drugs that have higher success rates, and challenges to building a drug company using machine learning.
Interviewees are:
Sanjiv Patel, President and CEO, Relay Therapeutics
Sean McClain, Founder and CEO, Absci
Jason Silvers, Chief Financial Officer, Generate Biomedicines